Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Targeting CCL3+mono like LSC overcomes chemotherapy resistance in NPM1 mutant AML

View Full Paper
Ask AI
Bookmark
Share

Authors

XJXi JiaSYSijian YuXXXi Xu

Discussion

Loading...

Member takes

Overview

Analysis reveals leukemia stem cells as prognostic biomarkers in acute myeloid leukemia, suggesting new treatment strategies.

Key Points

  • High-throughput screening identified drugs that enhance chemotherapy response in leukemia stem cell populations.
  • Single-cell RNA-sequencing unveiled unique monocyte-like leukemia stem cells linked to poor outcomes in acute myeloid leukemia.
  • Mechanistic studies showed phosphorylation of BCL2 contributes to treatment resistance in NPM1 mutant acute myeloid leukemia.
  • Investigation highlights the role of the immune microenvironment and potential therapeutic targets in managing chemotherapy resistance.

Cite This Study

Jia et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e575https://doi.org/10.1182/blood-2025-3511
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Proteogenomic analysis of NPM1-mutated AML reveals clinical heterogeneity related to differentiation states and mitochondrial metabolism2025
  2. 2Spatial single-cell multiomics of the bone marrow microenvironment in NPM1-mutant Acute Myeloid Leukemia2025
  3. 3Prognostic covariates associated with outcomes in patients with <i>NPM1</i>-mutated acute myeloid leukemia2025 · 3 citations
  4. 4Prognostic impact of co-occurring mutations in NPM1-mutated Acute Myeloid Leukemia2025
  5. 5Prognostic Value of Molecular and Clinical Features in Patients with NPM1 Gene Mutation in Acute Myeloid Leukemia2025 · 1 citations